Patients subgroups analysis
The PFS and OS of the clinical subgroups were analyzed, including bone marrow invasion, cell source, stage, International Prognostic Index (IPI) score, lactate dehydrogenase (LDH) level, β2 microglobulin (β2‐MG) level, age, sex, previous treatment line number, double expression, and refractory status. There were significant differences in PFS between the decitabine‐RDHAP and the RDHAP groups for the following subgroups of patients: female patients, refractory cases, patients aged >50 years, and patients with one previous line of therapy [GCB, germinal center B‐cell‐like lymphoma; HR, hazard ratio; IPI, International Prognostic Index; IPI score: low: 0–2, high: 3–5; LDH, lactate dehydrogenase, low LDH <245 U/L, high LDH ≥245 U/L; β2‐MG, β2 microglobulin, low β2‐MG <3 mg/L, high β2‐MG ≥3 mg/L. No treatment: rituximab, cisplatin, cytarabine, dexamethasone. Treatment: decitabine, rituximab, cisplatin, cytarabine, and dexamethasone.